Lack of Analgesic Activity of Morphine-6-glucuronide after Short-term Intravenous Administration in Healthy Volunteers
- 1 December 1997
- journal article
- clinical trial
- Published by Wolters Kluwer Health in Anesthesiology
- Vol. 87 (6) , 1348-1358
- https://doi.org/10.1097/00000542-199712000-00014
Abstract
Background: The analgesic activity of morphine-6-glucuronide (M-6-G) is well recognized for its contribution to the effects of morphine and its possible use as an opioid analgesic with a wider therapeutic range than morphine. The present study attempted to quantify the relative contribution of M-6-G to analgesia observed after systemic administration of morphine. Methods: In a placebo-controlled, sixfold crossover study in 20 healthy men, the effects of M-6-G were assessed at steady-state plasma concentrations of M-6-G identical to and two and three times higher than those measured after administration of morphine. Morphine and M-6-G were administered as an intravenous bolus followed by infusion over 4 h. Dosage A was M-6-G-bolus of 0.015 mg/kg plus infusion of 0.0072 mg x kg(-1) x h(-1). Dosage B was M-6-G-bolus of 0.029 mg/kg plus infusion of 0.014 mg x kg(-1) x h(-1). Dosage C was M-6-G-bolus of 0.044 mg/kg plus infusion of 0.022 mg x kg(-1) x h(-1). Dosage D was a morphine bolus of 0.14 mg/kg plus infusion of 0.05 mg x kg(-1) x h(-1) for 4 h. Dosage E was M-6-G combined with morphine (doses A + D). Dosage F was a placebo. The analgesic effects of M-6-G and morphine were measured before administration of the bolus and after 3.5 h using an experimental pain model based on pain-related cortical potentials and pain ratings after specific stimulation of the nasal nociceptor with short pulses of gaseous carbon dioxide. Results: Morphine significantly reduced subjective and objective pain correlates compared with placebo. In contrast, M-6-G produced no statistically significant effects. The addition of M-6-G to morphine did not increase the effects of morphine. Morphine produced significantly more side effects than M-6-G. Conclusion: After short-term intravenous administration at doses that produce plasma concentrations of M-6-G similar to those seen after administration of morphine, M-6-G had no analgesic effects in the present placebo-controlled study in healthy volunteers.Keywords
This publication has 56 references indexed in Scilit:
- Morphine-6-glucuronide concentrations and opioid-related side effects: a survey in cancer patientsPain, 1995
- The metabolite morphine-6-glucuronide contributes to the analgesia produced by morphine infusion in patients with pain and normal renal functionClinical Pharmacology & Therapeutics, 1992
- Morphine-3-glucuronide may functionally antagonize morphine-6-glucuronide induced antinociception and ventilatory depression in the ratPain, 1992
- Antinociceptive and ventilatory effects of the morphine metabolites: morphine-6-glucuronide and morphine-3-glucuronideEuropean Journal of Pharmacology, 1991
- Long lasting respiratory depression induced by morphine‐6‐glucuronide?British Journal of Clinical Pharmacology, 1989
- The spinal antinociceptive actions of morphine metabolites morphine-6-glucuronide and normorphine in the ratBrain Research, 1989
- Morphine-6-glucuronide: Analgesic effects and receptor binding profile in ratsLife Sciences, 1988
- POTENTIAL ANALGESIC CONTRIBUTION FROM MORPHINE-6-GLUCURONIDE IN CSFThe Lancet, 1987
- Biochemical basis for analgesic activity of morphine-6-glucuronide—I: Penetration of morphine-6-glucuronide in the brain of ratsBiochemical Pharmacology, 1973
- Analgesic Effect of Morphine GlucuronidesThe Tohoku Journal of Experimental Medicine, 1971